IonSource Daily Links to 
Mass Spectrometry, Biotechnology and Pharmaceutical  Industry News

 

IonSource Home | Disclaimer

Note: News stories may be minutes or several days old and should not be used for investment purposes.

-

-

-
07/14/14 Shimadzu Releases New "i-Series" of Integrated HPLCs, which Promote an Advanced Laboratory Environment
   
  Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening
   
07/10/14 Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma
   
07/07/14 BMS: Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen
   
07/04/14 GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation
   
  Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
   
  Shimadzu Releases New "i-Series" of Integrated HPLCs, which Promote an Advanced Laboratory Environment
   
07/03/14 GSK and Genmab receive EU authorisation for Arzerra™ (ofatumumab) as first-line treatment for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy
   
07/01/14 Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
   
  Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia
   
06/30/14 GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
   
  Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
   
  Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
   
06/27/14 GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL
   
  Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV
   
  Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
   
  BMS Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
   
  Regorafenib from Bayer Recommended for Approval in the European Union for the Treatment of Gastrointestinal Stromal Tumors
   
  Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C
   
06/25/14 GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
   
  The Bruker MALDI Biotyper™ Receives Clearance as a Medical Device from the China Food and Drug Administration (CFDA)
   
06/24/14 FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine
   
  BMS: Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
   
06/23/14 Agilent Technologies and Bruker to Provide Compatible Chromatographic Data System Software
   
06/19/14 Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients
   
  Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
   
06/18/14 Agilent Technologies Introduces Novel Synthetic Biology System to Accelerate Protein Engineering
   
06/17/14 Agilent Technologies Introduces Industry's First Exact Mass Pesticide Library for GC/Q-TOF
   
  Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research
   
  New AB SCIEX Triple Quad™ 3500 System Redefines Simplified Mass Spec
   
  "Shimadzu seeks to redefine quantitative proteomics by enabling powerful Skyline software support on its ultra-fast mass spectrometry platforms"
Collaboration between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington.
   
  Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
   
06/16/14 AB SCIEX Next-Generation Proteomics Platform Transforms Proteomics Research
   
  Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan
   
06/13/14 GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia
   
06/12/14 Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST
   
  BMS U.S. Court of Appeals Denies Appeal in Baraclude Patent Case
   
  Agilent Technologies Calls for Redemption of Outstanding 5.5 Percent Senior Notes Due September 2015
   
  ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
   
  FDA approves Bayer’s Gadavist (gadobutrol) Injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the United States
   
06/11/14 Bayer CropScience at the World Processing Tomato Congress in Italy:
Innovations and breeding advances to promote sustainability in the processing tomato industry
   
  Amgen: Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
   
  Agilent Technologies to Celebrate Customer Achievements at ASMS Conference
   
  GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD
   
  Nordion Receives Final Court Approval for Acquisition by Sterigenics
   
06/10/14 Novartis Foundation for Sustainable Development to work with Netherlands Leprosy Relief to help reduce leprosy transmission
   
06/9/14 New fast, simple food testing workflow from AB SCIEX advances food safety monitoring to mitigate risk
   
06/6/14 FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
   
06/5/14 GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
   
06/3/14 Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia
   
  Bayer: Contract for CEO Dr. Marijn Dekkers extended to the end of 2016
   
  Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi® achieved significant improvement in disease control
   
06/2/14 Roche acquires Genia Technologies to strengthen next generation sequencing pipeline
   
  Novartis study shows Zykadia(TM) shrank tumors in the majority of patients with ALK+ NSCLC, regardless of prior ALK treatment
   
  Novartis data at ASCO show LBH589 significantly improved progression-free survival in patients with multiple myeloma 
   
  Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
   
  Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma
   
  Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer
   
  BMS: Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival
   
06/1/14 Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
   
  GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
   
  Millenium: VELCADE® (bortezomib)-based Therapy Significantly Improved Progression-Free Survival Compared to Standard Therapy as Frontline Treatment of Patients with Mantle Cell Lymphoma in Phase 3 Study
   
05/31/14 Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
   
  Investigational Immunotherapy Anti-PDL1 (MPDL3280A) Shrank Tumors in 43 Percent of People With a Specific Type of Metastatic Bladder Cancer in a Genentech Study
   
  Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma
   
05/28/14 World MS Day: Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
   
05/27/14 Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR
   
  Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
   
  Serious Fraud Office Investigation GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK’s Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group’s commercial practices.
   
05/23/14 GSK and Genmab receive CHMP positive opinion for Arzerra (ofatumumab) in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who are not eligible for fludarabine-based therapy
   
  CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia
   
  FDA Approves First-Line Use of Vectibix® (Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer
   
  Biogen-Idec CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union
   
  Alcon receives positive CHMP opinion for Simbrinza®, a new fixed-dose combination medicine to treat patients with glaucoma
   
  Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
   
  Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
   
05/21/14 Thermo Fisher Scientific Declares Quarterly Dividend
   
05/20/14 Myriad: Prolaris(R) Test Predicts Mortality Risk in Prostate Cancer Biopsy Study
   
  GSK announces new commitment to improve access to vaccines with 5-year price freeze for countries graduating from GAVI Alliance support
   
  Amgen: The New England Journal Of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment
   
  Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults
   
  Merck Animal Health Announces FDA Approval of BRAVECTO™ (fluralaner)
   
  Bayer: South Korea becomes first country worldwide to approve new rice herbicide Council™
   
05/19/14 Life Tech: Next-Generation Flow Cytometry Instrument Broadens Analysis in Life Science Research
   
  Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
   
05/16/14 Abbott Expands Latin American Presence and Branded Generics Portfolio with Acquisition of CFR Pharmaceuticals
   
  Novartis: FDA issues Complete Response Letter for RLX030 for acute heart failure
   
05/15/14 Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary
   
  Millenium: Orteronel Plus Prednisone Improved Progression Free Survival in Men With Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase 3 Study
   
05/14/14 Shimadzu Releases GCMS-TQ8040 Triple Quadrupole Gas Chromatograph Mass Spectrometer
- Achieves Simultaneous Multicomponent Analysis and Ultra-High-Sensitivity Analysis in the Clinical, Food Safety, and Environmental Fields
   
05/13/14 GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
   
05/12/14 Agilent Technologies Collaborates With Seoul National University on New Research Center
   
  Agilent Technologies Introduces Next-Generation UHPLC Autosampler
   
  MERCK: FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
   
  Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
   
  Gilead Announces $5 Billion Share Repurchase Program
   
04/30/14 GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD
   
04/16/14 There has been recent publicity on cases of alleged misconduct by GSK employees in a number of countries. This is a result of details of these cases being made available to the media  4/16
   
  Bayer Focuses on Dialog with Greenpeace
Greenpeace publication does not allow for conclusions on the state of bee health in Europe
   
  Lilly: A Look at Minority Health in the U.S
   
04/15/14 GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)
   
04/14/14 Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1
   
  FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
   
  Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with
Cobicistat for People Living with HIV-1
   
04/11/14 Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
   
04/10/14 Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients
   
04/9/14 Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
   
04/7/14 Novartis meningitis B vaccine Bexsero® receives FDA Breakthrough Therapy designation in the US
   
  Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
   
  Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)
   
  Roche acquires IQuum to strengthen offerings in molecular diagnostics
   
  Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C
   
04/6/14 Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer
   
04/4/14 Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
   
04/3/14 AB Sciex Delivers Breakthrough for Therapeutic Biologics with Innovative CESI-MS
   
04/1/14 Newborn Screening Solution from AB SCIEX Provides Early Detection Indicators of Metabolic Disorders to Help Doctors in Europe Make Babies’ Health More Predictable
   
03/31/14 GSK: Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
   
  PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results
   
03/30/14 Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
   
03/28/14

Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma

   
  FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
   
03/25/14 Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
   
03/24/14 Thermo Fisher Scientific Completes Sale of Certain Biosciences Businesses to GE Healthcare
   
03/22/14

Mar-2014 New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) 

   
03/21/14 Genentech: FDA Approves Xolair® (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
   
03/20/14 Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold
   
03/12/14 Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)
   
03/07/14 Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
   
03/02/14 Genentech Provides Update On Phase III Study Of Onartuzumab in People With Specific Type of Lung Cancer
   
01/21/14 Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
   
  Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stoc
   
  GSK ViiV Healthcare’s new HIV medicine TivicayTM (dolutegravir) is approved in Europe
   
01/17/14 European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
   
01/16/14 Agilent Technologies Announces Agreement with Picometrics Technologies to Offer CE-LIF, CE-LIF-MS Solutions for Biopharmaceutical Applications
   
01/15/14 Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
   
01/14/14 Nektar Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
   
01/13/14 Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
   
  U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
   
  GSK Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
   
  BMS: U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes
   
  GSK Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)
   
01/09/14 Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
   
  GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)
   
01/06/14 Thermo Fisher Scientific Reaches Agreement to Sell its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare
   
  Observing the Living Nano World
Shimadzu Releases the SPM-8000FM High Resolution Scanning Probe Microscope - Even Capable of Measuring the Structure of Solid-Liquid Interfaces
   
12/19/13 Sandoz begins Phase III clinical trial for biosimilar adalimumab
   
  Nektar: New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
   
  Bristol-Myers Squibb Announces Dividend Increase
   
  Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
   
12/18/13 Sandoz receives first approval for AirFluSal® Forspiro®
   
  Agilent Technologies Introduces New Version of Intelligent System Emulation Technology for Liquid Chromatography Systems
   
 

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

   
  ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA™
   
  Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR® GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®)
   
  GSK announces $1 million innovation prize for bioelectronics research GSK is announcing today a $1 million dollar prize for innovation in the emerging area of bioelectronics research.
   
12/17/13 GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL) GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the US Food and Drug Administration (FDA) has granted Priority Review designation to the supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
   
  Depomed Acquires CAMBIA® (Diclofenac Potassium for Oral Solution) Migraine Medicine from Nautilus Neurosciences for $48.7 Million
   
  Agilent Technologies Appoints Fred Strohmeier Agilent Senior VP and President of Life Sciences and Diagnostics Group
   
  Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
   
  Merck: MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)
   
12/16/13 Gilead:Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
   
  Myriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study
   
12/13/13 Nektar: Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
   
  U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen
   
12/12/13 Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent
   
  Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual Allergy Immunotherapy Tablet
   
12/11/13 Bruker Corporation Announces Successful Installation of World’s First Compact 900 MHz Actively Refrigerated Magnet for NMR Spectroscopy at University of California, San Diego
   
  BMS: FDA Advisory Committee Votes on Investigational Medicine Metreleptin
   
12/10/13 Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931
   
12/09/13 Biogen: New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations
   
  Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
   
  Novartis drug Jakavi® improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
   
  Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak
   
  Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Myelofibrosis
   
  New five-year data support superiority of Novartis drug Tasigna® over Glivec® in newly diagnosed Ph+ CML patients
   
  Myriad Genetics Announces Cancer Research Collaboration With Janssen
   
  Millenium Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
   
  Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
   
12/08/13 Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
   
12/07/13 Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
   
  Analysis Suggests Increased Overall Survival with Use of Higher Cumulative Dose of VELCADE® (bortezomib) in Patients with Previously Untreated Multiple Myeloma
   
  Genentech’s Gazyva Helped People with One of the Most Common Forms of Blood Cancer Live Significantly Longer without Their Disease Worsening Compared to Rituxan in Phase III CLL11 Study
   
12/06/13 GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma
   
  Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
   
  U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
   
12/05/13 Strengthened presence in Latin American soybean market
Bayer CropScience to acquire Argentinian seed company FN Semillas S.A. more
   
12/03/13 Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting
   
12/02/13 Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™
   
11/28/13 Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle
   
  Regulatory Update - GSK receives positive CHMP opinion for Cervarix™ two-dose schedule Today, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™ [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant].
   
11/26/13 Merck Announces Increased Quarterly Dividend
   
  FDA Approves Merck’s NOXAFIL® (posaconazole) Delayed-Release Tablets
   
  Bruker Corporation Announces FDA Clearance to Market the MALDI Biotyper CA System
   
11/25/13 GSK Responds to FDA Decision on Avandia (rosiglitazone) GSK plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee review in June 2013.
   
  Bioinformatics Solutions Inc (BSI) released PEAKS Studio 7 today with notable advancements to de novo sequencing and label-free quantification for proteomics mass spectrometry
   
  H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (also referred to as Q-Pan H5N1 influenza vaccine) for the immunisation of adults 18 and older for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine.

   
  Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Tivicay® (dolutegravir).

   
  BMS: Xigduo™ (dapagliflozin and metformin hydrochloride) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
   
11/22/13 PEAKS Studio 7 Release: Identification through Label Free Quantification
   
11/21/13 Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
   
  Bayer CropScience hosts Horticulture Symposium in Bonn:
Fostering stakeholder dialogue to find new perspectives to reduce food losses in fresh produce and the food chain
   
  Researchers Solve a Mystery about Type 2 Diabetes Drug with Assistance from AB SCIEX Mass Spectrometry Technologies
   
11/20/13 Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer
   
11/19/13 Nektar: New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
   
  Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
   
11/18/13 Additional Interim Data for Merck’s Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma
   
  Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL® (posaconazole) antifungal.  Receives FDA Priority Review
   
  GSK: RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
   
  Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study
   
  European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection
   
  Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
   
11/14/13 Incyte Completes Offering of $750 Million of Convertible Senior Notes
   
 
   
11/13/13 Nektar: Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
   
  Bristol-Myers Squibb Announces Changes in Senior Management Team
   
  Biogen: Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A
   
11/12/13 Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
   
 

GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease

   
  American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's Ovarian Cancer Test, OVA1
   
11/07/13 Genentech’s Gazyva Helped People with One of the Most Common Forms of Blood Cancer Live Significantly Longer without Their Disease Worsening Compared to Rituxan in Phase III CLL11 Study
   
10/30/13 AB SCIEX Expands in Singapore to Drive Scientific Innovation
   
10/22/13 Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
   
  Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
   
  Agilent Technologies SureSelect Target Enrichment Now Available for Ion Proton Next-Generation Sequencing Systems
   
  Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
   
  GSK: ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
   
10/21/13 Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
   
  Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
   
  Bayer CropScience at the Annual Biocontrol Industry Meeting in Basel:
Biologicals: a modern element in integrated crop solutions
   
  Agilent Technologies Opens Technology Cooperation Center with Korea Advanced Institute of Science and Technology
   
10/18/13 Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
   
10/16/13 Gilead’s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy
   
10/15/13 Bayer CropScience appoints new members to its Executive Committee Investment and growth strategy set for systematic further implementation
   
10/14/13 Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
   
  Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
   
10/13/13 Genentech Announces Plans to Expand California Biologics Manufacturing Facilities
   
10/10/13 Bayer: Material-based design of sandwich elements with quality surfaces
   
  FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)
   
10/09/13 Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
   
  Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit
   
  Agilent Technologies and MRM Proteomics Introduce First Commercial Kits for Quality Control of MRM-Based Quantitative Plasma Proteomic Workflows
   
10/08/13 Merck: Results from a New Poll: Many Adults Aged 60-Plus Plan to Take Steps to Avoid Flu but Not Other Potentially Preventable Diseases Such as Shingles
   
  GSK: Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
   
10/05/13 Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
   
10/04/13 Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
   
  Bioge-Idec: New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
   
10/03/13 Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis
   
  Lilly: Single-Agent Ramucirumab Significantly Improves Overall Survival In Advanced Gastric Cancer Patients
   
10/02/13 Bayer: Bayer HealthCare Supports Fight Against Honeybee Parasite
   
10/01/13 Geron Completes Divestiture of Stem Cell Assets
   
  Biogen-Idec New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)
   
  Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3
   
  Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
   
  FDA grants Roche’s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
   
9/30/13 FDA Grants Genentech’s Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Breast Cancer
   
  Olivier Brandicourt appointed as new CEO of Bayer HealthCare more
   
  Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
   
  GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion
   
9/28/13 Amgen Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival
   
9/27/13 Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New Phase III Study
   
  Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and the Alzheimer's Disease Community
   
  Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy® (ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma
   
  GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia
   
9/26/13 Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
   
   
9/25/13 European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy
   
  Myriad Genetics' myPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint
   
  Data at ECTRIMS to confirm Novartis' Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS
   
9/24/13 Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
   
  GSK receives marketing authorisation from the European Commission for additional Revolade™ (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia
   
  BMS: New Phase III Data Showed Dapagliflozin Significantly Reduced HbA1c Compared to Placebo at 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with the Combination of Metformin Plus Sulfonylurea
   
  Shimadzu U.S.A. Manufacturing Obtains ISO 13485 Quality Management Standard Certification for LC and LCMS Instruments -Concentrating Manufacture of Clinical-Use Analytical Instruments in the U.S.-
   
9/23/13 Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
   
  Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection
   
  Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS
   
9/20/13 GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen in patients with Duchenne Muscular Dystrophy
   
  GSK: RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma
   
9/19/13 GSK: RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD
   
  GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
   
  Agilent Technologies to Separate into Two Industry-Leading Public Companies
   
  Agilent Technologies Combines Its Life Sciences and Diagnostics Businesses; Lars Holmkvist Named Group President
   
9/18/13 Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
   
9/16/13 GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma
   
  Bruker Introduces maXis™ HD Ultra-High Resolution QTOF at HUPO
   
9/13/13 GSK: FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia
   
  GSK statement in response to patent ruling reversal on Lovaza GlaxoSmithKline confirmed today that the Court of Appeals for the Federal Circuit has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza® (omega-3-acid ethyl esters).
   
9/12/13 GSK: ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
   
  Genentech: FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer
   
  Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer
   
9/11/13 AB SCIEX Receives Global Market Share Leadership Award for Mass Spectrometry from Frost & Sullivan
   
9/09/13 GSK reaches agreement to divest Lucozade and Ribena for £1.35 billion
   
9/03/13 Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
   
  Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
   
  Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
   
9/02/13 Shimadzu Releases LabSolutions CS Chromatography Data System - Achieves Integrated Management of Shimadzu Corporation's Analytical Instruments and Agilent Technologies' HPLCs
   
  Novartis' serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure
   
8/30/13 Dako and Omnyx Launch Digital Pathology Solution for Breast Cancer Diagnostics
   
  Abbott: Oral Nutritional Supplements in the Hospital Demonstrate Significant Health and Cost Benefits in New Research
   
8/29/13 Shimadzu New LabSolutions Direct Function Enables HPLC Access from a Smartphone or Tablet PC - Provides a remote operating environment for operations such as HPLC control, starting analysis, and analysis monitoring
   
  Pfizer Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial of Prevenar 13
   
  Agilent Technologies Invites Mass Spectrometry Users to September Training Workshops in England
   
8/27/13 Food Safety Testing, Environmental Analysis and Forensic Toxicology Made Simple with New AB SCIEX Software
   
8/26/13 Thermo Fisher Scientific Announces STEM Scholarship Program
   
  Shimadzu Launches Ver. 2 of Its GC/MS Metabolite Database - World's First Product Containing a Metabolite MRM Database to Support Triple Quadrupole Gas Chromatograph Mass Spectrometers
   
  Sangamo BioSciences to Acquire Ceregene
   
  Novartis holds annual healthcare entrepreneur competition to generate insight into healthcare and innovation of tomorrow
   
  Bayer HealthCare Contributes to Global Fight Against Parasitic Diseases
Research findings from new studies support international efforts against endoparasites, ectoparasites and protozoa more
   
  Agilent Technologies Launches New AssayMAP Peptide Sample-Prep Solution Agilent Technologies Inc. (NYSE: A) today announced the launch of its new AssayMAP peptide sample-prep solution, which offers automated protein digestion, peptide cleanup and fractionation in preparation for mass-spectrometry analysis.
   
8/25/13 Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
   
8/23/13 GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
   
8/22/13 Shimadzu Corporation Introduces the LCMS-8050 High-Sensitivity, Ultra-Fast Triple Quadrupole LC-MS/MS
   
8/21/13 Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients with Refractory Metastatic Pancreatic Cancer
   
  Abbott Completes Acquisition of IDEV Technologies
   
8/20/13 Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
   
8/19/13 Abbott Completes Acquisition of OptiMedica
   
8/16/13 Merck Animal Health Strengthens Commitment to Five Steps to Responsible Beef
   
8/15/13 Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis
   
8/14/13 Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
   
  GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
   
8/13/13 Lilly Announces Phase III Necitumumab Study Meets Primary Endpoint of Overall Survival Study found improved overall survival in patients with stage IV squamous NSCLC
   
8/12/13 ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1
   
8/8/13 GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
   
8/7/13 Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
   
  Regulatory Update - GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
   
8/5/13 Roche and the Medicines Patent Pool Sign Agreement to Increase Access to Medicines to Treat CMV infection in HIV-patients, a major cause of Blindness
   
8/1/13 FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age
   
7/30/13 New Data for Abbott’s Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
   
  Thermo Fisher Scientific Showcases Technologies to Improve Accuracy and Productivity in the Clinical Laboratory
   
  Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
   
7/29/13 GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases New extension of Synflorix vaccine supply agreement will help protect an additional 80 million children in the world’s poorest countries from pneumococcal disease.
   
  FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
   
  Depomed Announces Acquisition Of Lazanda® (fentanyl) Nasal Spray From Archimedes Pharma Limited
   
7/26/13 GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection Today, GlaxoSmithKline plc (GSK) announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for REVOLADETM (eltrombopag).
   
  Depomed Files Patent Infringement Lawsuit Against Zipsor® ANDA Filer
   
  Novartis receives positive CHMP opinion for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
   
7/25/13 Takeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based on Interim Analysis
   
  Consolidating sites for vegetable seeds and biologics research in the US:
Bayer CropScience plans to open integrated R&D site in West Sacramento, California
   
7/23/13 Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer Than Rituxan® in People with One of the Most Common Forms of Blood Cancer
   
7/17/13 Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
   
7/15/13 Thermo Fisher Scientific Wins Five R&D 100 Awards
   
  Agilent Technologies Triple Quadrupole ICP-MS Selected for R&D 100 Award
   
7/12/13 Thermo Fisher Scientific Declares Quarterly Dividend
   
7/10/13 AB Sciex to Drive Innovation in Separations Science with Combination of Eksigent Chromatography with Capillary Electrophoresis from Beckman Coulter Life Sciences
   
7/2/13 FDA Grants Genentech's Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
   
7/1/13 FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
   
6/26/13 Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Avian Influenza (H7N9) Virus
   
6/25/13 Thermo Fisher Scientific Significantly Expands R&D Capabilities in China
   
6/19/13 Bristol-Myers Squibb Announces Dividend
   
  Expansion of a global Wheat Breeding Network: Bayer CropScience opens Wheat Breeding Station in Milly-la-Forêt near Paris, France
   
  Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
   
6/18/13 GSK receives offer for its thrombosis brands and related manufacturing site
   
  Agilent Technologies Prices $600 Million of Senior Notes
   
6/17/13 Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
   
  DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration
   
  Roche position on the decision not to exercise the option for Seaside Therapeutics’ compound arbaclofen for autism and fragile X
   
6/16/13 Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
   
  Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
   
6/14/13 Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
   
  FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
   
6/13/13 Supreme Court Upholds Myriad's cDNA Patent Claims
   
  Roche's RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis
   
6/12/13 Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent
   
  Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
   
  Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
   
6/11/13 Thermo Fisher Announces Exercise of Over-Allotment Option in Common Stock Offering
   
6/10/13 Thermo Fisher Scientific Transforms Research and Applied Analysis with New-Generation Technologies at ASMS 2013
   
  Roche's RoACTEMRA approved in EU to treat children with rare form of arthritis
   
  Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
   
  GSK statement regarding 2010 Nature Medicine study
   
  Bruker Announces Powerful New Mass Spectrometry Systems and Solutions for Life-Science Research, Clinical Research, Pharma and Applied Markets
   
  AB SCIEX Advances the ‘Democratization’ of Mass Spectrometry for Applied Sciences
   
  AB SCIEX Enables Laboratories to Standardize on Single Software Platform for Accelerating Validation with New Version of Analyst Software
   
  Agilent Technologies Demonstrates New Generation of Ion Mobility Technology to Enhance High-Resolution Mass Spectrometry Capabilities
   
  Agilent Technologies Introduces Advanced Mass Spec Software to Optimize Food and Forensics Analyses and Biopharmaceutical Characterization
   
  Agilent Technologies Announces Enhancements for LC and LC/MS Systems
   
  New AB SCIEX Mass Spectrometry Solutions Improve Identification and Quantitation for Advanced Biological Research
   
  Agilent Technologies Launches RapidFire 365 High-Throughput Mass Spectrometry System
   
6/7/13 Thermo Fisher Announces Pricing of $2.2 Billion Common Stock Offering
   
  Shimadzu Releases LC/MS/MS Rapid Toxicology Screening System for Several Classes of Toxicological Compounds
   
  Shimadzu's New LC/MS/MS Method Package for Primary Metabolites Enables Fast, Simultaneous Analysis of 55 Primary Metabolites
   
  Shimadzu Releases LC/MS/MS Method Package for Lipid Mediators for Enhanced Profiling Analysis in Biological Samples
   
6/5/13 New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
   
6/3/13 GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
   
6/2/13 Roche's medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
   
6/1/13 AstraZeneca Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis(R)
   
  Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
   
5/31/13 FDA Issues Complete Response Letter on SEFELSA™ New Drug Application
   
5/24/13 Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic® for Beta-thalassemia
   
5/23/13 Takeda Announces Organizational Changes at Millennium: The Takeda Oncology Company
   
  Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
   
  GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
   
5/13/13 FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
   
  Patent Protection for TAL Effector Technology Enables Licensing Path for Life Technologies Customers
   
   Agilent Technologies Introduces AdvanceBio Peptide Mapping Columns
   
5/10/13 Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
   
  GSK: BREO™ ELLIPTA™ gains US approval for the treatment of COPD
   
  Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
   
5/09/13 GSK and Save the Children form unique partnership to save the lives of one million children An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children
   
  GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries.

 

   
  GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to Developing Countries through UNICEF Tender
   
  Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
   
5/08/13 Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
   
5/07/13 Millenium: Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients with Multiple Myeloma
   
  Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
   
  GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency GlaxoSmithKline (GSK) today announced progress on its commitment to share more detailed data from its clinical trials.

 

   
5/06/13 BMS: Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period
   
5/03/13 FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
   
  Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA® (efavirenz) in HIV-1 Infected Pediatric Patients
   
5/02/13 Gilead Reports Interim Data From Phase 2 LONESTAR Study
   
  Regulatory update: Trametinib US PDUFA date extended to 3 September 2013
   
5/01/13 Merck Announces New $15 Billion Share Repurchase Program
   
  GSK announces regulatory submission for umeclidinium monotherapy in US
   
  GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013.
   
4/30/13 GlaxoSmithKline plc today announced the submission of a regulatory application in the US for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD).
   
4/29/13 Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology
   
  Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
   
  Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
   
  Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development
   
4/26/13 Expanded Control of Shimadzu LC Systems for Empower(TM) Software - Waters Empower(TM) Software Now Controls Shimadzu Nexera X2 Series Products
   
  Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Avian Influenza (H7N9) Virus
   
4/25/13 Shimadzu's novel Imaging Mass Microscope, iMScope, enables optical microscopic observing samples to be mass spectrometric analyzed directly in the one instrument. - Application in disease biomarker research and biological function studies
   
  Roche Turkey visits hospitals to hand presents to children with cancer
   
4/23/13 Bayer CropScience and KeyGene enter into research agreement to develop improved crop varieties – initial focus on wheat more
   
  Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C
   
  Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients
   
4/22/13 Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
   
4/19/13 Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
   
  Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients
   
4/18/13 Bruker and the Genome British Columbia Proteomics Centre at the University of Victoria Announce Collaboration on Development of High Throughput iMALDI Assays
   
  AB SCIEX and LECO Partner to Offer Combined Solutions for GC/MS and LC/MS to Metabolomics Researchers
   
  Eurofins Collaborates with AB SCIEX and Phenomenex to Improve Analysis of Animal Feed
   
  Abbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric Intraocular Lens for Cataract Patients
   
4/17/13 GSK: FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD
   
  Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimer's Disease Research and Development
   
4/16/13 Bayer CropScience and Monsanto Enter into Cross-Licensing Agreements for Next-Generation and Enabling Technologies
   
  Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
   
4/16/13 Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
   
  Merck Opens New Manufacturing Facility in Hangzhou, China
   
  Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
   
4/15/13 Thermo Fisher Scientific to Acquire Life Technologies Corporation
   
  Agilent Technologies Introduces Enhanced NMR Data-Acquisition Software, Providing Optimal Speed and Spectral Quality with Minimal Effort
   
4/11/13 Life Technologies Launches New Bioinformatics Software Platform Enabling Bio-Design and Gene Synthesis from Next Generation Sequencing Data
   
  Roche Group posts strong sales growth in the first quarter
   
4/10/13 Pfizer Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
   
  Abbott's Galectin-3 Test Provides Doctors in Europe with New Tool for Assessing the Prognosis of Chronic Heart Failure Patient
   
  Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole)
   
4/08/13 Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C
   
4/07/13 Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients with Multiple Myeloma
   
4/05/13 Takeda and Millennium Announce Approval of ADCETRIS® (Brentuximab Vedotin) in Switzerland
   
4/04/13 The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis
   
  Roche launches new test for diagnosis and monitoring of thyroid cancer
   
4/03/13 Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2013
   
  GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
   
  GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK GlaxoSmithKline plc has announced the marketing authorization of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
   
4/02/13 Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations
   
  Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
   
  Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations
   
   

Company News

On-Line Magazines Hot News Sites
Abbott
Agilent
Amgen
AB SCIEX
Bayer
Biogen_Idec
Bruker
BMS Company
DepoMed
Vermillion
Eli Lilly
Genentech
Geron
Gilead
GSK
Incyte Gen.
Life Technologies
Leap Tech.
Nordion
Maxygen

Merck
Millennium
Myriad
Nektar
Novartis
Pfizer
Roche
Sangamo
Shimadzu
ThermoFisher
LCGC Magazine
Drug Discovery and Development Magazine
New Scientist

Proteomic Company News Links
Check out the Proteomics page at IonSource 

BioWire2K
Coranate
FierceBiotech
GenomeWeb
GE News of the Day
Moreover
ScienceNews On-Line
The Seattle Times
SF Gate Technology News

 

Archive of old news 

home | disclaimer
Copyright © 2001-2014  IonSource, LLC  All rights reserved. 
Last updated:  Monday, July 21, 2014 08:44:23 PM

Hit Counter